European patent application filed!


We filed a European patent application (EP 15175735.8) entitled “Novel PSMA-specific binding protein”. The invention relates to lipocalin Lcn2-derived binders with sub-nanomolar affinity for human prostate-specific membrane antigen. These reagents have been developed in collaboration with A. Skerra group (Technische University, Munich, Germany) and are aimed for the use in the diagnosis and/or therapy of prostate cancer.